Molidustat (INN; Bay 85-3934) is a drug which acts as an HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease. Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC prefix |
|
c |
|
CAS number |
|
H |
|
IUPAC name |
|
KEGG |
|
n |
|
O |
|
PubChem |
|
SMILES |
|
StdInChI |
|
StdInChIKey |
|
synonyms |
|
UNII |
|
width |
|
has abstract |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
FDA UNII code |
|
KEGG |
|
PubChem |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |